Table 3.

Results of reverse MR analysis between liability to ALS and risk of autoimmune disorders

Outcome	N SNPs	N, proxy SNPs	r2	F-statistics	Inverse variance weighted			Weighted median			MR Egger
					OR	CI	pval	OR	CI	pval	OR	CI	pval
Asthma	10	0	0.004	63.343	1.016	0.959–1.077	0.590	1.032	0.969–1.098	0.340	0.983	0.853–1.132	0.817
CD	10	0	0.004	63.343	1.066	0.951–1.194	0.270	1.078	0.927–1.253	0.331	1.200	0.920–1.566	0.215
CeD	2	0	0.023	139.698	2.351	1.167–4.735	0.017	NA	NA	NA	NA	NA	NA
IBS	10	0	0.004	63.343	0.999	0.940–1.062	0.972	0.993	0.925–1.066	0.843	0.966	0.832–1.121	0.272
MS	8	3	0.004	64.947	0.991	0.834–1.178	0.058	1.102	0.933–1.302	0.140	1.254	0.740–2.124	0.267
PBC	6	1	0.004	63.009	1.024	0.816–1.286	0.834	1.028	0.778–1.359	0.838	1.137	0.666–1.941	0.663
PSC	9	0	0.004	65.403	1.244	0.991–1.561	0.059	1.289	0.959–1.733	0.095	1.057	0.575–1.940	0.865
PsO	3	1	0.007	112.585	0.834	0.373–1.867	0.660	0.689	0.428–1.108	0.119	7.243	1.329–39.472	0.262
RA	8	0	0.004	67.835	1.025	0.913–1.151	0.243	1.053	0.910–1.220	0.360	1.173	0.820–1.677	0.941
T1D	10	0	0.004	63.343	0.990	0.811–1.209	0.923	1.148	0.899–1.467	0.271	1.478	0.999–2.188	0.087
UC	10	0	0.004	63.343	1.010	0.862–1.184	0.899	1.046	0.884–1.238	0.604	0.866	0.592–1.266	0.480
SLE	9	0	0.004	65.403	1.197	0.970–1.477	0.093	1.243	0.943–1.638	0.093	1.245	0.726–2.134	0.451

The ORs are effects of liability to ALS on the risk of autoimmune disorders

CI confidence interval, MR Mendelian randomization, SNP single nucleotide polymorphism, r² proportion of variance in exposure variable explained by SNPs, F-statistics “strength” of the instrumental variable, proxy SNPs SNPs that are LD “proxies”, CD Crohn’s disease, CeD celiac disease, IBS irritable bowel syndrome, MS multiple sclerosis, PBC primary biliary cirrhosis, PSC primary sclerosing cholangitis, PsO psoriasis, RA rheumatoid arthritis, T1D type 1 diabetes, UC ulcerative colitis, SLE systemic lupus erythematosus